Home
  • Donate money to KEI
  • Listserves
  • Main Areas of Work
  • Events
  • Publications
  • Blogs
  • About KEI

Knowledge Ecology International

Attending and mending the knowledge ecosystem

Navigation

  • Site Map
  • Recent posts
  • Feed aggregator
  • Polls
  • Groups

Round II of the Paris Accord took place in Paris on October 23 and 24, 2009.

Book navigation

  • Right to Read for Persons with Reading Disabilities
  • About KEI
  • Access to Medical Technologies
  • Berne Convention Appendix Regarding Special Provisions Regarding Developing Countries
  • Competition Policy
  • Data points on prices of medical technologies
  • Databases
  • Enforcement and Remedies to Infringement
  • Events
  • General Access to Knowledge Issues
  • Government Funded Inventions
  • Knowledge Governance Fora
    • The Anti-Counterfeiting Trade Agreement (ACTA)
    • World Intellectual Property Organization (WIPO)
    • European Union
    • Non Communicable Disease (NCD) negotiations
    • Trans-Pacific Partnership Agreement (TPPA)
    • UNESCO
    • United States Trade Representative (USTR)
    • World Health Organization (WHO)
      • CEWG: WHO Consultative Expert Group on R&D Financing
      • Expert Working Group on R&D Financing
        • A closer look at the WHO EWG endorsed proposals on funding product development partnerships
        • Briefing on the Report of the WHO Expert Working Group on R&D Financing
        • Corporate sponsors of the George Institute
        • KEI Comments to EWG 2nd Web-based Public Hearing: Defending the Status Quo, or Roadmap for Change?
        • Open Letter to the WHO EB from Cecilia López Montaño, EWG member
        • Submissions of Member States and Stakeholders to WHO Expert Working Group on R&D Financing
        • The WHO EWG's proposals for taxes to fund medical R&D
        • The baffling WHO EWG analysis of innovation inducement prizes
        • WHO Expert Working Group on R&D Financing (EWG)
        • World Health Organization (WHO) to hold consultation on report of Expert Working Group on R&D financing
        • KEI comments to WHO EWG
      • 1998/1999 debate over 52.19, the WHO Revised Drug Strategy
      • KEI March 2, 2007 letter to WHO on the Model Essential Medicines List
      • The World Health Assembly takes step back, but leaves door open, for medical R&D Treaty
      • Views on the 60th World Health Assembly IGWG resolution
      • Views on the 61st World Health Assembly adoption of Global Strategy on Public Health, Innovation and Intellectual Property
      • WHO issues mild statement on transit of medicines
      • Why does Bill Gates oppose discussions of a medical R&D treaty at the World Health Organization?
      • WikiLeaks cable details UK/US strategy during IGWG negotiations in 2007
    • World Trade Organization (WTO)
  • Main Areas of Work
  • Medical diseases, conditions and technologies
  • Nuclear Proliferation
  • Patent Policy
  • Prizes to stimulate innovation
  • Publications and Research Notes
  • Test Data
  • Timelines
  • Transparency

User login

What is OpenID?
  • Log in using OpenID
  • Cancel OpenID login
  • Create new account
  • Request new password
Home » Blogs » James Love's blog

KEI comments to WHO EWG

  • View
  • What links here
Submitted by James Love on 16. April 2009 - 10:32
  • EWG
  • Generic competition
  • I+A
  • innovation plus access
  • Pricing of medical technologies
  • WHO/IGWG

KEI filed comments with the WHO Expert Working Group. A copy is available here.

‹ World Health Organization (WHO) to hold consultation on report of Expert Working Group on R&D financing up 1998/1999 debate over 52.19, the WHO Revised Drug Strategy ›
  • James Love's blog
  • Printer-friendly version
  • Add new comment
  • Send to friend

Support KEI

WASHINGTON 1621 Connecticut Ave. NW, Suite 500, Washington, DC 20009 /TEL: +1.202.332.2670 · FAX +1.202.332.2673 GENEVE 1 Route des Morillons, CP 2100, 1211 Genève 2, Switzerland TEL: +41.22.791.6727
THEME DESIGN Copyright © 2009 under GPL by Tribute Media. Site Powered by Drupal.